The aim of the study was lo evaluate the activity of vinorelbine (VNLB) in a population of ad vanced ovarian cancer potients, with porticular attention to defining its role in platinum-resistant disease.
V 1NORELBINE (VNLB) is a semisynthetic vinca al
kaloid analog that acts by promoting depolymeriza tion and inhibiting the assembly of mitotic microtubules at a concentration that does not affect axonal microtu bules,' and may therefore be active against cancer cells and less neurotoxic than vinca a!kaloids. Preclinical stud ies have shown that VNLB is more active than conven tiona! vinca a!kaloids,2 and phase I studi es have ascer tained that the drug can be safely given at a dose of 25 to 30 mg/m 2 intravenously (IV) weekIy but further dose escalation is limited by the onset of severe neutropenia and peripheral neurotoxicity. 3 In phase II studies, VNLB has been shown to be active in non-small-celliung can cer, breast cancer. and Hodgkin's disea~e"
Two early reports of phase II studies have also sug gested that the activity of VNLB (alone or in combina tion) may be promising in advanced ovarian cancer. 5 . 6 These data prompted us to study its activity in advanced epithelial ovarian cancer, with particular attention to de termining its efficacy in platinum-resistant cases.
adconfidence interval, 5.1 %to 31.9%). Ali the respanses occurred in the subgroup af 24 platinum-resistant cases, in whom the response rate was 21 % (95% exad confi· dence interval, 7.1% lo 42.1 %). Seven patients became stabilized on VNLB, and 27% of the cases showed a re duction in serum cancer antigen 125 (CA 12S)levels. G31
G4 side effects consisted of neutropenia, anemia, and worsening of preexisting peripheral neuropathy. No treatment-related deaths occurred. Conc:lusion: VNLB led lo a 21 % response rate in tbe population of heavily pretreated and platinum-resistant avarian cancer patients. Further studies of VNLB alone or in combination with taxanes are warranted in patients with less pretreatment.
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PATIENTS ANO METHODS

Eligibility Criteria arui Study Protocol
Patients with radiologically measurable advanced epithelial ovar ian cancer were eligible for lhe sludy; those with only assessable disease were noI enrolled. AlleasI one previous first-line treatment with platinum compaunds was required. bUI tbe number of previous chernotherapy regimens was not limited and previous radiotherapy was also allowed. The other eligibility criteria were as follows: age :5 75 years. Eastem Cooperative Oncology Group perfonnance status O lO 2. absolute neutrophil count tANC) "" 1.5OO/ILL, platelet count "" loo,OOO/ILL. hemoglobin level "" 8 gldL. lotal bilirubin level :5 1.5 mgldL. and serurn creatinine level :5 1.2 mgldL. Each patient provided infonned consent, and the study was approved by our Institutional Review Board. Concomitant peripheral neuropathy "" grade 3 (National Cancer lnstitute criteria) was a contraindication to study admission.
Eligible patients underwent chest x-ray, radiologic examination of the abdornen and pelvi s, gynecologic exarnination. and electrocar diography, all of which were repeated every 2 months thereafter. Routine hematochemistry (hemogram. blood urea nitrogen, serum creatinine, urie acid, electrolytes. glycemia, transaminases. lOtaI bili rubin, alkaline phosphatase. and serum electrophoresis) was under taken at baseline; the hemogram was repeated weekly and the re maining evaluations were repeated every 3 weeks. Cancer antigen 125 tCA 125) serum levels were assessed at baseline and al monthly intervals. VNLB (Navelbine; Pierre Fabre Pharma, Bizanos, France) was administered as an IV bolus at a dose of 25 mglm 2 weekly, and tumor respanse was evaluated after 2 months. In the case of an objective respanse or disease stabilization, treatmenl was eontinued; otherwise. il was stopped. Patients whose disease had stabilized after 4 monlhs of treatment were kept in the follow-up study. Criteria for treatment delays and dose-reductions were as follows. Seven days after the drug infusion, an ANC was condueted. If this resulted in less than 1,500/ p.L, the seeond infusion was delayed for a further 3 days and the eycle repeated on the tentb day if the ANC was 2: 1.5OO/ILL. If the ANC was still less than I, 5OO/ILL 21 days after 2547 VlNORELBINE IN OVARIAN CANCER the last drug injection, the dose was reduced by 25% for the next cycle. No granulocyte colony-stimulating factors were used during the mal. For hemoglobin levels less than 8 gldL at the moment of drug infusion, a RBC transfusion was given, and the cycle was repeated after 3 days if the hemoglobin level was '" 8 gldL; other wise. further transfusions were given unlil the hemoglobin leve) was "" 8 gldL. Treatment was stopped in the case of grade 3 or 4 periph era] neuroloxicity or constipation. Turnor response was assessed according IO standard criteria 7 ; in the case of lesions thal were mea surable by physicaI examination, response was confirmed radiologi cally. Toxicity was graded aecording to the Nalional Caneer Institute c1assification. 8 Patienls were considered assessable only if they had undergone alleasI three cycIes of chemotherapy. Response duration was calculaled from Ihe lime of response documenlation, whereas the lime lO treatrnenl failure and overall survival were caIculated from Ihe time of tre.atment initiation and eslimated using the Kaplan Meier method. ExacI 95% confidence intervals were computed for the response rales in the whole populalion and in Ihe subgroup of platinum-resistanl patients.
Criteria to Define Platinum Responsiveness
The criteria used IO assess platinum responsiveness have been previously reported 9 and can be summarized as follows. Patients were defined as platinum-resistant if the disease had progressed during adrninistration of a platinum-containiug regirnen, or had stabi lized or regressed by less !han 50% after platinum·containing chemo therapy given unti I the cumulative dose of cisplatin or carboplatin had reached a lotal of 450 or 1,800 rnglm 2 , respectively. Patienls were defined as plalinum-sensitive if they had responded al least partially after a treatrnent thal inc\uded platinum compounds. The stalus of patients without radiologic or surgical evidence of response or progression after a previous platinum therapy was defined as Wldetennined. The piatinum-free intervaI was nOI used in the assess ment of responsiveness IO platinum compounds. The responsiveness of palients wbo had received Iwo lines of platinum-containing regi mens before enlering the study was evaluated on the basis of results achieved with Ihe Iasl regimen.
RESULTS
Patient Characteristics
Thirty-three patients were recruited between January 1993 and December 1994; their main characteristics are Iisted in Table l . AlI patients had received previous che motherapy, the median number being two (range, one to five). Ali patients had been previously treated with plati nurn compounds, and 10 had received previous treatment with paclitaxeL Ali of the patients had radiologically measurable dis ease as required by the eligibility criteria; furthermore, the disease in 16 patients was also measurable by physicai exarnination (12 cases with abdominal-pelvic masses and four with superficial lymph nodes). Eight patients had concomitant assessable sites (two with diffuse abdominal skin infiltration, one with Iytic bone lesions, and five with pelvic masses).
On the basis of the criteria far platinum responsiveness used in this study, there were 24 platinum-resistant, four platinum-sensitive, and five undetermined cases. It should be pointed out that two of four sensitive cases had been in pathologically complete remission for lO and Il months, respective1y, whereas the remaining two were in partial remission and were treated with VNLB 1 year after the last platinum dose. No radiologic or surgical evaluation of responsiveness to a platinum-containing chemotherapy was available for the five undetermined cases, but ali were treated with VNLB at least 7 months after the last platinum-containing cycle (range, 7 to 84). Comparison to the conventional criteria for determining platinum re sponsiveness 1o showed no difference in the evaluation of responsiveness, except for the fact that the conventional criteria would have divided the group of 24 platinum resistant patients into two different subgroups of 15 pri mary-and nine secondary-resistant cases.
Treatment Administration
A tomI of 260 VNLB cycles were given, with a mean number of eight per patient. The mean delivered dose intensity was 2.4 mg/m 2 /d, 67% of the planned amount (3 .6 mg/m 2 /d), because 60% of the cycles were delayed (a mean of five delayed cycles per patient). Twenty-one of 33 patients (64%) required a treatment delay in accor dance with the criteria already described; in particular, the causes of delay were neutropenia (ANC < 1,500/fJ.L at the moment of drug infusion) in 16 patients, anemia (hemoglobin level < 8 g/dL at the moment of drug infu sion) in three, and anemia plus neutropenia in two. No dose-reductions were needed. 
Antitumor Activity
Ali 33 eligible patients were assessable for response: there were one complete response ([CR] 3%), four partial responses ([PRs] 12%), seven cases of stable disease (21%), and 21 cases of progressive disease (64%), for an overall response rate of 15% (95% exact confidence interval, 5. I % to 31.9%). The five responses were among the 24 resistant cases (21 % OR; 95% exact confidence interval 7.1% to 42.1%). There was no response among the four platinum-sensitive patients or the five patients whose responsiveness was undetennined. Characteristics of the responding patients are listed in Table 2 , and it must be emphasized that alI but one had received VNLB as a third-line therapy. With regard to the activity of VNLB among the lO patients who had been previously treated with paclitaxel. one whose disease had progressed on paclitaxel, responded to VNLB. and two who had previously responded to paclitaxel had disease progres sion on VNLB. According to the conventional criteri a of platinum responsiveness, two of five responses were achieved by nine secondary-resistant cases, and the re maining three occurred in the group of 15 primary-resis tant patients.
For the seven patients whose disease stabilized, the med.ian duration of stabilization was 6 months (range, 4 to 12). It is important lO point out that one of the stabiliza tions lasted for 12 months (VNLB being a fifth-line treat ment); another in a platinum-resistant patient lasted for 6 months and was associated with a decrease in serum CA 125 levels of 67% from baseline values; and a third, in a patient who also received VNLB as fifth-line therapy, was a minor response (tumor reduction in the liver and stabilization of a pelvic mass) associated with a 44% reduction in CA 125 levels. Serum CA 125 levels de creased in a totaI of seven of 26 assessable patients, the mean reduction being 63%. According to criteria reported by Rustin et allI to define tumor response on the basis of multiple serum CA 125 evalualions, two of 20 patients achieved a tumor remission, one of whom also showed a radiologic response. The median lime to trealment fail ure and overall survival duration were 4 months (range, l to 14) and lO months (range, 2 to 20), respectively. Ten patients received further trealment after disease pro gression during VNLB (four with paclitaxel, two with docetaxel, and four with tamoxifen), with only a minor response observed in one of the patients on paclitaxel.
Tolerability
Side effects experienced by 33 assessable patients are listed in Table 3 . Neutropenia, anemia, and worsening of a preexisting peripheral neuropathy were the only G3 side effects. Five patients needed RBC transfusions. Two patients stopped VNLB treatment because of toxicity (G3 peripheral neurotoxicity in both cases) . No toxic deaths were reported, and none of the patients refused to con tinue VNLB or to receive the trealment at the due time. mately 80% of advanced ovarian cancer patients will need second-line therapy during the treatment program. Unfor tunately, the discovery of active drugs in platinurn-resis tant disease is rare, although the use of taxanes over the last few years has led to important data.
IZ2l
In this study of VNLB in a population of heavily pre treated patients, we observed a 15% response rate with a mean delivered dose-intensity thal was 67% of Ihe planned leveL The main resull was a 21 % response rate in 24 platinwn-resistant cases; in facl, alI of the responses occurred in this subset of patients, although it is impossi ble to evaluate the drug's activily in the group of patients with platinum-sensitive disease because this included on1y four cases. Two trials that evaluated VNLB in ad vanced ovarian cancer have been reported. 5 . 6 The tirst evaluated VNLB 30 mglm 2 weekly in a population of 32 pretreated patients 5 and recorded five objective remissions (one CR), for an overall response rate of 15%; three of these responses occurred in patienls whose disease had progressed while on previous chemotherapy. Twenty-six percent of the cycles were delayed and 12% were given al reduced dose, mainly as a resull of neutropenia. The other trial combined VNLB with hexamethylmelamine in a group of 17 pretreated patients, with VNLB given at a dose of 20 mg/m 2 weekly.6 There were one pathologic PR and five clinical responses (two CR), for a response rate of 36%; two of the remissions were obtained in plati num-resistant patients.
Both of these studies suggested that VNLB may be active in advanced ovarian cancer, but they lack a clear description of the platinum-responsiveness of the treated patients. The difference in the present study is that pa tients were classified according to previous response to platinum compounds, and this has made it possible to investigate the activity of VNLB in platinum-resistant disease, which is the ideal target to evaluate new drugs in ovarian cancer.
The crileria used to determine platinum responsiveness in this study virrually overlap with the conventional crite ria, lO the only differences beiog the further division of platinum resistance into primary-and secondary-resistant cases (used in the conventional criteria) and the adrnission of patients whose disease had stabilizedlregressed less than 50% when treated with platinum into the category of resistant cases only if they had received a determined cumulative dose of platinum compounds (used in the cri teria of this study). Nevertheless, whichever criteria for platinwn responsiveness are used, the response rate to VNLB in the platinwn-resistant patients of this srudy re mains at 21 %.
As is also suggested by the conventional criteria for platinum responsiveness,IO patients who experienced tu rnor remission during treatment with platinum compounds but had a platinum-free interval of less than 6 months were not considered resistant, because such patients may still respond to platinum compounds even if the probabil ity of response is directly related lo the platinum-free interval and the extremely brief respanse obtained may not be meaningfuI.
22 -2.1 Noninclusion of these patients in the category of resistant cases makes the criteria to assess platinum resistance very rigid and therefore the evaluation of the investigated drug very accurate. This choice may be supported by an editorial that analyzed the results of a second-line paclitaxel study in which platinum resis tance was classified as either absolute (progression during platinum) orrelative (relapse within 6 rnonths or stabiliza tioo after platinum). It is interesting that the responses to secood-line paclitaxel varied and seemed to be better in relatively resistant patients, although the analysis is lim ited by the small number of patients included in the two categories? 6 In terrns offuture investigations, it would be interesting to study the activity of VNLB at a higher dose-intensity. In this subset of heavily pretreated patients it seerns difti cult to improve dose-intensity, because even though we planned to adrninister the drug to patients with grade l neutropenia CANC 2: 1,500/j.tL), it was not possible to give more than 67% of Ihe originally planned dose. An improvement in dose-intensity might be obtained in less heavily pretreated patients or if weekly VNLB is associ ated with administration of a granulocyte colony-stim ulating factor. However, although it might theoretically improve the drug's antitumor activity, a greater dose intensity rnight also lead to increased toxicity (peripheral neurotoxicity and anemia), and since the second-line treatment of ovarian cancer is only palliative, this may be a major concerno A further area of development for VNLB is the possi bility of combining it with taxanes. VNLB acts by inhibi tion of microtubule assembly and promotion of microtu buie depolymerization. whereas the taxanes promote the assembly and inhibit the depolymerization-both agents inhibit celi rnitosis. In vitro studi es have demonstrated that VNLB and paclitaxel act synergistically when ex posed to two human breast cancer cell lines. but it is important to stress that the combination loses activity when cells are exposed to paclitaxel 24 hours before addi tion of VNLB?7 Preclinical models have confirmed the synergistic activity of the VNLB-paclitaxel combina tion,28 and synergy has also been demonstrated when do cetaxel and VNLB are concomitantly given to mice bear ing solid tumors?9 In a recent clinical study that tested the combination of VNLB and paclitaxel,3O seven patients with pretreated lung or breast cancer were enrolled onto a dose-finding study that evaluated fixed-dose VNLB (25 mglm 2 IV on days l and 8) plus paclitaxel given at two different doses (90 mglm 2 over 3 hours for the first three
BAJffiA ET AL patients and 175 mglm 2 over 3 hours for the last four); granulocyte colony-stimulating factors were also rou tinely used. AlI of the patients received VNLB before paclitaxel. It is clear from this preliminary experience that the combination of the two drugs leads to severe granulocytopenia despite the use of granulocyte colony stimulating factors, and therefore other schedules rnight be explored, particularly in chemotherapy-naive pa tients.
In conclusion, in the present trial VNLB led to a 15% response rate in a population of heavily pretreated ovarian cancer patients and, more important1y, a 21 % response rate in the subgroup of 24 patients with platinum-resistant disease. Together with the data from two previous trials, these results suggest that VNLB may be useful in ovarian cancer and that future studies in a less heavily pretreated population are warranted. Furthermore, preclinical and early clinical data suggest that the association of VNLB and taxanes may lead to a synergy that should soon be tested in ovarian cancer.
